ANCA-associated vasculitides: Pathogenetic aspects and current evidence-based therapy

被引：11
作者：
Holle, J. U. [1 ]
Gross, W. L.
机构：
[1] Univ Hosp Schleswig Holstein, Dept Rheumatol, D-23538 Lubeck, Germany
来源：
JOURNAL OF AUTOIMMUNITY | 2009年 / 32卷 / 3-4期
关键词：
ANCA-associated vasculitis; Wegener's granulomatosis; Evidence-based therapy; EULAR recommendations; CHURG-STRAUSS-SYNDROME; ANTINEUTROPHIL CYTOPLASMIC AUTOANTIBODIES; REFRACTORY WEGENERS-GRANULOMATOSIS; ANTIBODY-ASSOCIATED VASCULITIS; TNF-ALPHA BLOCKADE; SYSTEMIC-LUPUS-ERYTHEMATOSUS; TERM-FOLLOW-UP; RANDOMIZED-TRIAL; MYCOPHENOLATE-MOFETIL; POLYARTERITIS-NODOSA;
D O I：
10.1016/j.jaut.2009.02.019
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
A lot of progress has been made regarding the therapy of ANCA-associated vasculitides in the past decades. Cyclophosphamide still is standard therapy for remission induction in generalized disease, however, duration and cumulative dose of cyclophosphamide have been curtailed successfully to reduce toxicity. MTX is a safe alternative for remission induction in early systemic disease and medications available for remission maintenance have been extended. Rituximab and TNFalpha-antagonists represent promising options for refractory disease. The current evidence of therapy of ANCA-associated vasculitides is summarized in this review. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码：163 / 171
页数：9
相关论文
共 50 条
[41]   Pathogenesis and treatment of ANCA-associated vasculitides [J].
Kallenberg, C. G. M. .
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2015, 33 (04) :S11-S14
[42]   An immunogenetic perspective of ANCA-associated vasculitides [J].
A. Kocaaga ;
M. Kocaaga .
Egyptian Rheumatology and Rehabilitation, 2022, 49
[43]   Diagnostic Approach to ANCA-associated Vasculitides [J].
Gaffo, Angelo L. .
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2010, 36 (03) :491-+
[44]   ANCA-associated vasculitides, an update 2017 [J].
de Groot, Kirsten .
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2017, 142 (15) :1133-1138
[45]   The environment, geoepidemiology and ANCA-associated vasculitides [J].
Chen, Min ;
Kallenberg, Cees G. M. .
AUTOIMMUNITY REVIEWS, 2010, 9 (05) :A293-A298
[46]   B cell therapy in ANCA-associated vasculitis: current and emerging treatment options [J].
McClure, Mark ;
Gopaluni, Seerapani ;
Jayne, David ;
Jones, Rachel .
NATURE REVIEWS RHEUMATOLOGY, 2018, 14 (10) :580-591
[47]   Cellular immune regulation in the pathogenesis of ANCA-associated vasculitides [J].
von Borstel, Anouk ;
Sanders, Jan Stephan ;
Rutgers, Abraham ;
Stegeman, Coen A. ;
Heeringa, Peter ;
Abdulahad, Wayel H. .
AUTOIMMUNITY REVIEWS, 2018, 17 (04) :413-421
[48]   Mechanisms of Disease: pathogenesis and treatment of ANCA-associated vasculitides [J].
Kallenberg, Cees G. M. ;
Heeringa, Peter ;
Stegeman, Coen A. .
NATURE CLINICAL PRACTICE RHEUMATOLOGY, 2006, 2 (12) :661-670
[49]   Is There Still a Role of Plasma Exchange in the Current Management of ANCA-Associated Vasculitides? [J].
Task Toyoda ;
Max Yates ;
Richard A. Watts .
Current Rheumatology Reports, 2022, 24 :111-117
[50]   T-helper cells as new players in ANCA-associated vasculitides [J].
Abdulahad, Wayel H. ;
Lamprecht, Peter ;
Kallenberg, Cees G. M. .
ARTHRITIS RESEARCH & THERAPY, 2011, 13 (04)
12345